Brilaroxazine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Leokitcat (talk | contribs)
119 edits
Update and add refs superseding data from previous one
Leokitcat (talk | contribs)
119 edits
Update refs and add some pharmacokinetic data
Line 22: Line 22:
<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound = >99%
| metabolism = Liver (mostly via CYP3A4 (64%) and 2D6 (17%)) <ref name="Cantillon2018"> {{cite journal| vauthors = Cantillon M, Ings R, Prakash A, Bhat L |title=A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder|journal=European Journal of Drug Metabolism and Pharmacokinetics|volume=43|year=2018|pages=573–585|doi=10.1007/s13318-018-0472-z|pmid=29619682}}</ref>
| metabolism =
| elimination_half-life = 42-48 hours <ref name="Cantillon2017">{{cite journal| vauthors = Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L |title=Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder|journal=Schizophrenia Research|volume=189|year=2017|pages=126-133|doi=10.1016/j.schres.2017.01.043|pmid=28215471}}</ref>
| elimination_half-life =
| excretion =
| excretion =


Line 51: Line 51:
}}
}}


'''Brilaroxazine''' (developmental code names '''RP-5063''' and '''RP-5000'''), also known as '''oxaripiprazole''',<ref name="pmid29767995" /><ref name="Jordan2018" /> is an investigational [[atypical antipsychotic]] which is under development by Reviva Pharmaceuticals for the treatment of [[schizophrenia]] and [[schizoaffective disorder]].<ref name="PhRMA2014">{{cite report | title = Medicines in Development for Mental Health | year = 2014 | publisher = Pharmaceutical Research and Manufacturers of America | url = http://www.phrma.org/sites/default/files/pdf/2014-mental-health-report.pdf | page = 20 | access-date = 2015-05-19}}</ref><ref name="KösterCarbon2014">{{cite journal | vauthors = Köster LS, Carbon M, Correll CU | title = Emerging drugs for schizophrenia: an update | journal = Expert Opinion on Emerging Drugs | volume = 19 | issue = 4 | pages = 511–31 | date = December 2014 | pmid = 25234340 | doi = 10.1517/14728214.2014.958148 | s2cid = 42729570 }}</ref><ref name="PharmMed2014">{{cite journal|title=Drug Development in Schizophrenia: Summary and Table|journal=Pharmaceutical Medicine|volume=28|issue=5|year=2014|pages=265–271|issn=1178-2595|doi=10.1007/s40290-014-0070-6|s2cid=8513976}}</ref><ref name="Rajagopal2017">{{cite journal| vauthors = Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY |title=RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia|journal=Behavioural Brain Research|volume=332|year=2017|pages=180-199|doi=10.1016/j.bbr.2017.02.036|pmid=28373127}}</ref><ref name="Cantillon2017">{{cite journal| vauthors = Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L |title=Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder|journal=Schizophrenia Research|volume=189|year=2017|pages=126-133|doi=10.1016/j.schres.2017.01.043|pmid=28215471}}</ref> Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of [[bipolar disorder]], [[major depressive disorder]], [[psychosis]]/[[psychomotor agitation|agitation]] associated with [[Alzheimer's disease]], [[Parkinson's disease]] psychosis, [[attention deficit hyperactivity disorder]] (ADD/ADHD), and [[autism]].<ref name="Reviva2015a">{{cite web | title = About Us | publisher = Reviva Pharmaceuticals | url = http://revivapharma.com/about-us/ | access-date = 2015-05-19}}</ref><ref name="Reviva2015b">{{cite web | title = Product Pipeline | publisher = Reviva Pharmaceuticals | url = http://revivapharma.com/product_pipeline/ | access-date = 2015-05-19}}</ref> As of July 2023, it is in [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for schizophrenia.<ref name="Reviva2015a" /><ref name="Reviva2015b" />
'''Brilaroxazine''' (developmental code names '''RP-5063''' and '''RP-5000'''), also known as '''oxaripiprazole''',<ref name="pmid29767995" /><ref name="Jordan2018" /> is an investigational [[atypical antipsychotic]] which is under development by Reviva Pharmaceuticals for the treatment of [[schizophrenia]] and [[schizoaffective disorder]].<ref name="Cantillon2017" /><ref name="Rajagopal2017">{{cite journal| vauthors = Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY |title=RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia|journal=Behavioural Brain Research|volume=332|year=2017|pages=180-199|doi=10.1016/j.bbr.2017.02.036|pmid=28373127}}</ref><ref name="PhRMA2014">{{cite report | title = Medicines in Development for Mental Health | year = 2014 | publisher = Pharmaceutical Research and Manufacturers of America | url = http://www.phrma.org/sites/default/files/pdf/2014-mental-health-report.pdf | page = 20 | access-date = 2015-05-19}}</ref><ref name="KösterCarbon2014">{{cite journal | vauthors = Köster LS, Carbon M, Correll CU | title = Emerging drugs for schizophrenia: an update | journal = Expert Opinion on Emerging Drugs | volume = 19 | issue = 4 | pages = 511–31 | date = December 2014 | pmid = 25234340 | doi = 10.1517/14728214.2014.958148 | s2cid = 42729570 }}</ref><ref name="PharmMed2014">{{cite journal|title=Drug Development in Schizophrenia: Summary and Table|journal=Pharmaceutical Medicine|volume=28|issue=5|year=2014|pages=265–271|issn=1178-2595|doi=10.1007/s40290-014-0070-6|s2cid=8513976}}</ref> Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of [[bipolar disorder]], [[major depressive disorder]], [[psychosis]]/[[psychomotor agitation|agitation]] associated with [[Alzheimer's disease]], [[Parkinson's disease]] psychosis, [[attention deficit hyperactivity disorder]] (ADD/ADHD), and [[autism]].<ref name="Reviva2015a">{{cite web | title = About Us | publisher = Reviva Pharmaceuticals | url = http://revivapharma.com/about-us/ | access-date = 2015-05-19}}</ref><ref name="Reviva2015b">{{cite web | title = Product Pipeline | publisher = Reviva Pharmaceuticals | url = http://revivapharma.com/product_pipeline/ | access-date = 2015-05-19}}</ref> As of July 2023, it is in [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for schizophrenia.<ref name="Reviva2015a" /><ref name="Reviva2015b" />


==Pharmacology==
==Pharmacology==


===Pharmacodynamics===
===Pharmacodynamics===
Brilaroxazine is described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the [[dopamine]] and [[serotonin]] [[neurotransmitter]] systems compared to other antipsychotics.<ref name="Cantillon2017" /><ref name="Cantillon2013">{{cite web | title = Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder | author = Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat | publisher = American Society of Clinical Psychopharmacology | year = 2013 | url = http://pmg.joynadmin.org/documents/1005/649206e29a38ca2a705d9c72.pdf | access-date = 2015-05-19}}</ref> Specifically, it acts as a [[partial agonist]] of the [[D2 receptor|D<sub>2</sub>]], [[D3 receptor|D<sub>3</sub>]], and [[D4 receptor|D<sub>4</sub> receptor]]s and of the [[5-HT1A receptor|5-HT<sub>1A</sub>]] and [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]]s, and as an [[receptor antagonist|antagonist]] of the [[5-HT6 receptor|5-HT<sub>6</sub>]] and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s.<ref name="PharmMed2014" /><ref name="Cantillon2017" /><ref name="Cantillon2013" /> Brilaroxazine has high [[affinity (pharmacology)|affinity]] for the D<sub>2S</sub>, D<sub>2L</sub>, D<sub>3</sub>, D<sub>4.4</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, and [[Histamine H1 receptor|H<sub>1</sub> receptor]]s, and moderate affinity for the [[D1 receptor|D<sub>1</sub>]], [[D5 receptor|D<sub>5</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]], 5-HT<sub>6</sub> receptors, the [[serotonin transporter]], and the [[alpha-1B adrenergic receptor|α<sub>1B</sub>-adrenergic receptor]].<ref name="Cantillon2013" /> It lacks significant affinity for the [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]], and [[muscarinic acetylcholine receptor]]s, as well as for the [[norepinephrine transporter|norepinephrine]] and [[dopamine transporter]]s.<ref name="Cantillon2013" /><ref name="PipelineReview2012">{{cite web | title = Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder | author = Reviva Pharmaceuticals | publisher = PipelineReview | year = 2012 | url = http://www.pipelinereview.com/index.php/2012031247361/Small-Molecules/Reviva-Pharmaceuticals-Announces-Enrollment-of-Patients-in-Phase-2-Clinical-Study-of-RP5063-for-the-Treatment-of-Schizophrenia-and-Schizoaffective-Disorder.html}}</ref>
Brilaroxazine is described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the [[dopamine]] and [[serotonin]] [[neurotransmitter]] systems compared to other antipsychotics.<ref name="Cantillon2017" /><ref name="Cantillon2013">{{cite web | title = Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder | author = Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat | publisher = American Society of Clinical Psychopharmacology | year = 2013 | url = http://pmg.joynadmin.org/documents/1005/649206e29a38ca2a705d9c72.pdf | access-date = 2015-05-19}}</ref> Specifically, it acts as a [[partial agonist]] of the [[D2 receptor|D<sub>2</sub>]], [[D3 receptor|D<sub>3</sub>]], and [[D4 receptor|D<sub>4</sub> receptor]]s and of the [[5-HT1A receptor|5-HT<sub>1A</sub>]] and [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]]s, and as an [[receptor antagonist|antagonist]] of the [[5-HT6 receptor|5-HT<sub>6</sub>]] and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s.<ref name="Cantillon2017" /><ref name="PharmMed2014" /><ref name="Cantillon2013" /> Brilaroxazine has high [[affinity (pharmacology)|affinity]] for the D<sub>2S</sub>, D<sub>2L</sub>, D<sub>3</sub>, D<sub>4.4</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>7</sub>, and [[Histamine H1 receptor|H<sub>1</sub> receptor]]s, and moderate affinity for the [[D1 receptor|D<sub>1</sub>]], [[D5 receptor|D<sub>5</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]], 5-HT<sub>6</sub> receptors, the [[serotonin transporter]], and the [[alpha-1B adrenergic receptor|α<sub>1B</sub>-adrenergic receptor]].<ref name="Cantillon2013" /> It lacks significant affinity for the [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]], and [[muscarinic acetylcholine receptor]]s, as well as for the [[norepinephrine transporter|norepinephrine]] and [[dopamine transporter]]s.<ref name="Cantillon2013" /><ref name="PipelineReview2012">{{cite web | title = Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder | author = Reviva Pharmaceuticals | publisher = PipelineReview | year = 2012 | url = http://www.pipelinereview.com/index.php/2012031247361/Small-Molecules/Reviva-Pharmaceuticals-Announces-Enrollment-of-Patients-in-Phase-2-Clinical-Study-of-RP5063-for-the-Treatment-of-Schizophrenia-and-Schizoaffective-Disorder.html}}</ref>


==Chemistry==
==Chemistry==

Revision as of 21:09, 14 July 2023

Brilaroxazine
Clinical data
Other namesRP-5063; RP-5000; Oxaripiprazole[1][2]
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Protein binding>99%
MetabolismLiver (mostly via CYP3A4 (64%) and 2D6 (17%)) [4]
Elimination half-life42-48 hours [3]
Identifiers
  • 6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC22H25Cl2N3O3
Molar mass450.36 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl
  • InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)
  • Key:PMKMNTBZJOXTJW-UHFFFAOYSA-N

Brilaroxazine (developmental code names RP-5063 and RP-5000), also known as oxaripiprazole,[1][2] is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.[3][5][6][7][8] Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.[9][10] As of July 2023, it is in phase III clinical trials for schizophrenia.[9][10]

Pharmacology

Pharmacodynamics

Brilaroxazine is described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the dopamine and serotonin neurotransmitter systems compared to other antipsychotics.[3][11] Specifically, it acts as a partial agonist of the D2, D3, and D4 receptors and of the 5-HT1A and 5-HT2A receptors, and as an antagonist of the 5-HT6 and 5-HT7 receptors.[3][8][11] Brilaroxazine has high affinity for the D2S, D2L, D3, D4.4, 5-HT1A, 5-HT2A, 5-HT7, and H1 receptors, and moderate affinity for the D1, D5, 5-HT3, 5-HT6 receptors, the serotonin transporter, and the α1B-adrenergic receptor.[11] It lacks significant affinity for the 5-HT1B, 5-HT2C, α2-adrenergic, and muscarinic acetylcholine receptors, as well as for the norepinephrine and dopamine transporters.[11][12]

Chemistry

Brilaroxazine is identical to aripiprazole in chemical structure except for the replacement of one of the carbon atoms in aripiprazole's quinolinone ring system with an oxygen atom, resulting instead in a benzoxazinone ring system. The drug is also closely related structurally to brexpiprazole and cariprazine.

Recent Developments

In June 2023, Reviva Pharmaceuticals announced successful enrollment over 80% of the participants in its schizophrenia phase III clinical trial. This pivotal study, which includes clinical sites across the United States, Europe, and Asia, aims to assess the efficacy and longer term safety of brilaroxzaine in schizophrenia. A letter from the CEO released in January 2023 noted no major adverse drug effects were observed as of that date and that enrollment was progressing well. The anticipated study completion date in late 2023. If successful, commercial availability is anticipated in early 2026.

See also

References

  1. ^ a b Modica MN, Lacivita E, Intagliata S, Salerno L, Romeo G, Pittalà V, Leopoldo M (October 2018). "Structure-Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update". J Med Chem. 61 (19): 8475–8503. doi:10.1021/acs.jmedchem.7b01898. PMID 29767995.
  2. ^ a b Jordan, Ann Westcot (14 September 2018). Antidepressants: History, Science, and Issues. ISBN 9781440839276.
  3. ^ a b c d Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L (2017). "Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder". Schizophrenia Research. 189: 126–133. doi:10.1016/j.schres.2017.01.043. PMID 28215471.
  4. ^ Cantillon M, Ings R, Prakash A, Bhat L (2018). "A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder". European Journal of Drug Metabolism and Pharmacokinetics. 43: 573–585. doi:10.1007/s13318-018-0472-z. PMID 29619682.
  5. ^ Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY (2017). "RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia". Behavioural Brain Research. 332: 180–199. doi:10.1016/j.bbr.2017.02.036. PMID 28373127.
  6. ^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. p. 20. Retrieved 2015-05-19.
  7. ^ Köster LS, Carbon M, Correll CU (December 2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–31. doi:10.1517/14728214.2014.958148. PMID 25234340. S2CID 42729570.
  8. ^ a b "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
  9. ^ a b "About Us". Reviva Pharmaceuticals. Retrieved 2015-05-19.
  10. ^ a b "Product Pipeline". Reviva Pharmaceuticals. Retrieved 2015-05-19.
  11. ^ a b c d Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat (2013). "Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder" (PDF). American Society of Clinical Psychopharmacology. Retrieved 2015-05-19.{{cite web}}: CS1 maint: multiple names: authors list (link)
  12. ^ Reviva Pharmaceuticals (2012). "Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder". PipelineReview.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Brilaroxazine&oldid=1165385668"